ArticleDigestive diseases and sciences2026
Clinical Effectiveness and Safety Evaluation of SpyGlass Versus X-Ray-Assisted ERAT in the Treatment of Acute and Chronic Appendicitis.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND STUDY
aimTo evaluate the clinical effectiveness and safety of SpyGlass versus X-ray-assisted endoscopic retrograde appendicitis therapy (ERAT) in the treatment of acute and chronic appendicitis. PATIENTS AND
methodsA retrospective analysis was conducted on 153 patients with acute, subacute, and chronic appendicitis admitted to the Endoscopy Center of the First Affiliated Hospital with Nanjing Medical University between June 2022 and July 2024. According to the different endoscopic methods, the patients were divided into the X-ray group and the SpyGlass group. The treatment success rate, procedure duration, VAS pain scores before and after surgery, length of hospital stay, time to resume diet, hospitalization costs, complications, and 12-month recurrence were analyzed, respectively.
resultsBaseline clinical characteristics showed no intergroup differences. Compared with the X-ray assisted group, the SpyGlass group achieved higher treatment success, shorter operation and fasting recovery time, and lower 12-month recurrence, while the X-ray group had lower hospitalization costs. Hospital stay length and 6-h postoperative VAS reduction were comparable between groups. Univariate and multivariate logistic regression identified no independent risk factors for procedural success; Cox regression for recurrence revealed migrated abdominal pain and appendicolith as independent risk factors.
conclusionBoth SpyGlass and X-ray assisted ERAT are safe and effective for the treatment of acute and chronic appendicitis. However, patients in the SpyGlass group demonstrated superior procedural success alongside reduced long-term recurrence. Overall, ERAT represents an optimal minimally invasive, non-surgical approach for the clinical management of acute and chronic appendicitis.
Indexed as
Identifiers
42749956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.